Literature DB >> 1532163

Specific cytolysis of HIV-infected cells by lymphocytes armed with bifunctional antibodies.

H Okada1, H Momota, T Azuma, T Hattori, N Okada.   

Abstract

The Fab' fragment of a monoclonal antibody (mAb) directed to CD3 (a portion of the T cell receptor) and the Fab' or F(ab')2 fragment of an mAb to HIV were combined to generate bifunctional antibody (BFA) consisting of antiCD3-Fab' conjugated with anti-HIV-Fab' (Fab'/Fab') or antiCD3-Fab' conjugated with anti-HIV-F(ab')2 (Fab'/F(ab')2), respectively. In the presence of these BFA, HIV-infected target cells were cytolysed by peripheral blood lymphocytes. Treatment of lymphocytes with Fab'/F(ab')2 type BFA rendered the lymphocytes significantly cytotoxic to HIV-infected target cells. Since BFA-armed lymphocytes can react on HIV-infected cells regardless of histocompatibility, lymphocytes from healthy donors could be armed with BFA for treatment of HIV-infected patients including those who do not exhibit histocompatibility with the lymphocyte donor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532163     DOI: 10.1016/0165-2478(92)90122-5

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  3 in total

1.  The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vitro.

Authors:  T Hideshima; A Iwasaki; M Baba; Y Yamashita; T Shirakusa; H Okada
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

2.  Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.

Authors:  Johannes Brozy; Erika Schlaepfer; Markus Muenz; Roberto F Speck; Christina K S Mueller; Mary-Aude Rochat; Silvana K Rampini; Renier Myburgh; Tobias Raum; Peter Kufer; Patrick A Baeuerle
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 3.  Bispecific antibodies: Potential immunotherapies for HIV treatment.

Authors:  Giulia Fabozzi; Amarendra Pegu; Richard A Koup; Constantinos Petrovas
Journal:  Methods       Date:  2018-10-22       Impact factor: 3.608

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.